We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Use of Acetyl Salicylic Acid and Terbutalin in Assisted Reproductive Techniques (ART)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00518141
Recruitment Status : Completed
First Posted : August 20, 2007
Last Update Posted : July 21, 2011
Sponsor:
Information provided by:

Study Description
Brief Summary:
This study aims to determine the possible effects of Acetyl Salicylic Acid (ASA) and Terbutalin on ART treatment.

Condition or disease Intervention/treatment
Reproductive Techniques, Assisted Drug: Acetyl Salicylic Acid and Terbutalin

Detailed Description:
This study aims to determine the possible effects of ASA and Terbutalin on ART treatment.

Study Design

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 300 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Use of Acetylsalicylic Acid and Terbutalin in ART
Study Start Date : March 2006
Primary Completion Date : May 2009
Study Completion Date : May 2009

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arms and Interventions

Arm Intervention/treatment
Experimental: 1
FER
Drug: Acetyl Salicylic Acid and Terbutalin
ASA 75 mg, Terbutalin 5mg
No Intervention: 2
FER
Experimental: 3
SET
Drug: Acetyl Salicylic Acid and Terbutalin
ASA 75 mg, Terbutalin 5mg
No Intervention: 4
SET
Experimental: 5
DET
Drug: Acetyl Salicylic Acid and Terbutalin
ASA 75 mg, Terbutalin 5mg
No Intervention: 6
DET


Outcome Measures

Primary Outcome Measures :
  1. Pregnancy [ Time Frame: 7 weeks ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 39 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Infertile women below 39 years of age

Exclusion Criteria:

  • Women who may react allergically to the drugs administered
  • Women with hyperthyroid or IDDM
  • Women who do not want to participate in the study
  • Women who are unable to give informed, written consent.
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00518141


Locations
Norway
STHF, Kvinneklinikken, Fertilitetsklinikken Sor
Porsgrunn, Telemark, Norway, 3901
Sponsors and Collaborators
Sykehuset Telemark
Investigators
Principal Investigator: Jarl A Kahn, Dr. med STHF, Kvinneklinikken, Fertilitetsklinikken Sor
More Information

Responsible Party: Jarl Kahn, Fertilitetsklinikken Sør
ClinicalTrials.gov Identifier: NCT00518141     History of Changes
Other Study ID Numbers: S-06085 (REK)
First Posted: August 20, 2007    Key Record Dates
Last Update Posted: July 21, 2011
Last Verified: July 2011

Additional relevant MeSH terms:
Salicylic Acid
Salicylates
Aspirin
Terbutaline
Anti-Infective Agents
Antifungal Agents
Keratolytic Agents
Dermatologic Agents
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Fibrinolytic Agents
Fibrin Modulating Agents
Platelet Aggregation Inhibitors
Antipyretics
Bronchodilator Agents
Autonomic Agents
Anti-Asthmatic Agents
Respiratory System Agents
Sympathomimetics
Tocolytic Agents
Reproductive Control Agents